Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A NEW diabetes treatment has been turned down for use in Scotland by the NHS on cost grounds.
Tresiba (Insulin degludec) is the first long-lasting insulin that lets patients manage blood glucose levels with a daily injection that can be taken at any time of the day.
In a trial involving 7000 patients with Type 2 diabetes, the new insulin reduced the risk of night hypoglycaemia by up to 36%, compared with standard insulin.
http://www.eveningtimes.co.uk/news/diabetes-treatment-ruled-too-expensive-122126n.20885993
Tresiba (Insulin degludec) is the first long-lasting insulin that lets patients manage blood glucose levels with a daily injection that can be taken at any time of the day.
In a trial involving 7000 patients with Type 2 diabetes, the new insulin reduced the risk of night hypoglycaemia by up to 36%, compared with standard insulin.
http://www.eveningtimes.co.uk/news/diabetes-treatment-ruled-too-expensive-122126n.20885993